Category Archives: Imunotherapies

Article on latest develpments

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Article by Dr. Shaw

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA. http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, Lung cancer, Potential Treatments, Research | Leave a comment

Two FDA approvals for immunotherapy for NSCLC

In October 2015 FDA approves two immunotherapys nivolumab (Opdivo) and pembrolizumab (Keytruda) for non small cell lung cancer. While not targeted at ALK they are new treatments they could be tried by an ALK+ lung cancer patient, especially if their … Continue reading

Posted in Imunotherapies, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Imunotherapy update for NSCLC (not squamous cell)

On April 17 it was announced that a large study of Bristol-Myers Squibb Co’s Opdivo treatment has been halted after proving the drug is effective against the most common form of lung cancer,┬ánon-small cell lung cancer (NSCLC). When a similar … Continue reading

Posted in Imunotherapies, Lung cancer, Regulatory applications & approvals, Research | Leave a comment

Imunotherapy approved for Squamous NSCLC

On March 4 the FDA approved Opdivo (Nivolumab) by Bristol-Myers for the treatment of Squamous NSCLC who have previously been treated by at least one chemotherapy. Patients do not have to have PD-L1 expression in order to get the drug. … Continue reading

Posted in Imunotherapies, Lung cancer, Regulatory applications & approvals | Leave a comment

Pfizer update

Pfizer announced that in 2015 the are going to start trials that combine imunitherapy (PDL-1 and PD-1) drugs with its two ALK inhibitor drugs. Pfizer is planning a potential pivotal study of PF-06463922 starting in 2015. By the end of … Continue reading

Posted in 3922 - lorlatinib by Pfizer, crizotinib - Xalkori from Pfizer, Imunotherapies | Leave a comment